Kymera Therapeutics (NASDAQ:KYMR) Trading Down 5.9% – Time to Sell?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price traded down 5.9% during mid-day trading on Monday . The company traded as low as $43.79 and last traded at $43.92. 150,689 shares traded hands during trading, a decline of 74% from the average session volume of 579,921 shares. The stock had previously closed at $46.67.

Wall Street Analyst Weigh In

KYMR has been the topic of several recent research reports. BTIG Research initiated coverage on Kymera Therapeutics in a research report on Tuesday. They set a “buy” rating and a $60.00 price target on the stock. Guggenheim boosted their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Truist Financial reaffirmed a “buy” rating and set a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. UBS Group reduced their price target on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Finally, BMO Capital Markets initiated coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective for the company. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $53.88.

Kymera Therapeutics Stock Performance

The firm’s 50-day moving average price is $46.29 and its two-hundred day moving average price is $42.78. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of -19.25 and a beta of 2.16.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.01. The company had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics’s revenue was down 20.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.90) EPS. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its stake in Kymera Therapeutics by 5.8% during the third quarter. FMR LLC now owns 5,109,141 shares of the company’s stock worth $241,816,000 after purchasing an additional 282,301 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Kymera Therapeutics by 7.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock valued at $218,587,000 after buying an additional 308,954 shares during the period. Jennison Associates LLC lifted its stake in Kymera Therapeutics by 85.8% during the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock worth $37,754,000 after acquiring an additional 368,394 shares in the last quarter. Eventide Asset Management LLC boosted its holdings in Kymera Therapeutics by 9.9% during the 3rd quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock valued at $24,039,000 after acquiring an additional 45,803 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its position in Kymera Therapeutics by 11.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock valued at $21,458,000 after acquiring an additional 47,507 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.